What is your opinion on the use of biologics in patients with asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome?
Paul O’Byrne: We have very good high-quality evidence to support the use of biologics, particularly those that bind to interleukin 5, in severe refractory eosinophilic asthma. There are studies currently underway, and we have recently published a small study of the use of this approach in COPD with persistent airway eosinophilia which did not show benefit.
What we do not have are studies looking at larger populations of patients with asthma–COPD overlap syndrome. Although, I understand, some larger studies are underway and we will have information probably quite soon about the potential value in that population.